1. A 61-year-old man with type 2 diabetes has been taking glimepiride 4 mg daily for two years with an HbA1c of 7.2 percent. Two weeks after a once-weekly GLP-1 receptor agonist was added without other changes, he reports several episodes of tremor, sweating, and hunger in the late morning, each relieved by eating. He has been eating noticeably less because of early satiety. A capillary glucose during one episode was 54 mg/dL. What is the most appropriate next step?
A) Stop the GLP-1 receptor agonist permanently, as it is directly causing glucose-independent insulin release
B) Add bedtime basal insulin to stabilize the glucose
C) Reduce the glimepiride dose by approximately 25 to 50 percent and continue the GLP-1 receptor agonist with glucose monitoring
D) Reassure the patient that these are expected initiation symptoms unrelated to glucose and make no change
E) Discontinue glimepiride and replace it immediately with prandial insulin
ANSWER: C
Rationale:
The episodes are documented hypoglycemia arising from the additive effect of a non-glucose-gated sulfonylurea plus reduced food intake from GLP-1 receptor agonist appetite suppression. The GLP-1 receptor agonist does not cause hypoglycemia alone, so the correct step is to reduce the sulfonylurea dose by roughly 25 to 50 percent and continue the GLP-1 receptor agonist with glucose monitoring.
Option A: Option A is incorrect because the GLP-1 receptor agonist works in a glucose-dependent manner and is not the agent driving the lows; stopping it is not the appropriate fix.
Option B: Option B is incorrect because adding basal insulin would increase, not decrease, hypoglycemia risk.
Option D: Option D is incorrect because the documented glucose of 54 mg/dL with classic adrenergic symptoms relieved by eating is hypoglycemia, not the nausea of initiation.
Option E: Option E is incorrect because replacing the sulfonylurea with prandial insulin adds a further hypoglycemia risk and does not address the problem; dose reduction of the secretagogue is the measured response.
2. A 48-year-old woman with type 2 diabetes and obesity requests a GLP-1 receptor agonist for weight loss and glycemic control. Her history is notable for a mother and brother with medullary thyroid carcinoma diagnosed in the setting of multiple endocrine neoplasia type 2 (MEN2), and she carries the familial RET mutation. What is the most appropriate decision?
A) Do not prescribe any GLP-1 receptor agonist, because a personal or family history of medullary thyroid carcinoma or MEN2 is an absolute (black-box) contraindication to the class
B) Prescribe a GLP-1 receptor agonist but obtain serum calcitonin every 3 months as a safety measure
C) Prescribe a GLP-1 receptor agonist at a reduced dose, since the contraindication applies only at full dose
D) Prescribe a GLP-1 receptor agonist after a normal baseline thyroid ultrasound clears her for therapy
E) Prescribe an exendin-4-based agent specifically, since the contraindication applies only to human GLP-1-based agents
ANSWER: A
Rationale:
A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) is an absolute, black-box contraindication that applies to the entire GLP-1 receptor agonist class. With a strong familial history and the RET mutation, no agent in the class should be prescribed.
Option B: Option B is incorrect because the contraindication is absolute; routine calcitonin monitoring does not convert a contraindicated patient into a candidate.
Option C: Option C is incorrect because the contraindication is not dose-dependent and is not waived at a lower dose.
Option D: Option D is incorrect because a normal thyroid ultrasound does not lift the black-box contraindication in a patient with this genetic and family history.
Option E: Option E is incorrect because the contraindication applies across the whole class, including exendin-4-based agents, not only human GLP-1-based agents.
3. A 55-year-old man started oral semaglutide 8 weeks ago and reports excellent adherence, never missing a dose. His HbA1c is unchanged. On questioning, he takes the tablet each morning with his coffee and breakfast because "it is easier to remember with food." What is the most likely explanation for the lack of effect?
A) Oral semaglutide is inactive and only the injectable form lowers glucose, so the route must be changed
B) He has developed neutralizing antibodies to semaglutide that have abolished the response
C) The dose is subtherapeutic and must be tripled regardless of administration technique
D) Taking the tablet with coffee and food rather than on an empty stomach with up to 120 mL of water and a 30-minute wait has impaired the SNAC-dependent gastric absorption, which is already only about 1 to 2 percent bioavailable
E) Oral semaglutide requires a high-fat meal for absorption, so his breakfast was not fatty enough
ANSWER: D
Rationale:
Oral semaglutide depends on SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) to permeabilize the gastric mucosa, and its absolute bioavailability is only about 1 to 2 percent and highly sensitive to conditions. It must be taken on an empty stomach with no more than 120 mL of water and at least 30 minutes before food, other fluids, or medications. Taking it with coffee and breakfast markedly impairs absorption, explaining the absent response despite adherence.
Option A: Option A is incorrect because oral semaglutide is active and effective when taken correctly; the route does not need to change.
Option B: Option B is incorrect because the clinical picture points to an administration error, not neutralizing antibodies.
Option C: Option C is incorrect because tripling the dose without correcting technique does not address the absorption failure.
Option E: Option E is incorrect because the drug must be taken on an empty stomach; a fattier meal would worsen, not improve, absorption.
4. A 67-year-old woman with type 2 diabetes has an HbA1c of 6.8 percent on metformin alone. She had a myocardial infarction 14 months ago and has established atherosclerotic cardiovascular disease. Her clinician is considering whether to add a second agent. Based on current guidance, what is the most appropriate recommendation?
A) Make no change, because her HbA1c is at target and no additional agent could be justified
B) Add a GLP-1 receptor agonist with proven cardiovascular benefit, which is recommended as a preferred second agent in established atherosclerotic disease regardless of baseline HbA1c
C) Add a sulfonylurea, since it is the preferred second agent for patients with cardiovascular disease
D) Add a GLP-1 receptor agonist only if her HbA1c later rises above 9 percent
E) Avoid a GLP-1 receptor agonist because cardiovascular disease is a contraindication to the class
ANSWER: B
Rationale:
For a patient with type 2 diabetes and established atherosclerotic cardiovascular disease, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended as a preferred second agent regardless of baseline HbA1c, because the indication is cardiovascular risk reduction rather than glycemic need.
Option A: Option A is incorrect because an at-target HbA1c does not preclude adding an agent for cardiovascular benefit; the addition is driven by her vascular risk.
Option C: Option C is incorrect because a sulfonylurea is not the preferred second agent for cardiovascular benefit and lacks the outcome evidence of GLP-1 receptor agonists.
Option D: Option D is incorrect because the recommendation does not depend on the HbA1c rising above a threshold; it applies regardless of baseline HbA1c.
Option E: Option E is incorrect because established cardiovascular disease is an indication for preferred use, not a contraindication.
5. A 52-year-old man with long-standing type 2 diabetes presents with an HbA1c of 11.2 percent. A recent dilated eye exam documented moderate non-proliferative diabetic retinopathy. His clinician plans to start a high-potency GLP-1 receptor agonist. Which management approach best addresses the retinopathy concern?
A) Lower the HbA1c as quickly as possible to remove the glycemic insult and protect the retina
B) Avoid all glucose-lowering intensification indefinitely because any treatment will damage the retina
C) Proceed at maximum dose immediately, since retinopathy is unrelated to the rate of glycemic change
D) Substitute a DPP-4 inhibitor, which uniquely prevents retinopathy progression
E) Pace the glycemic correction to avoid a rapid HbA1c drop and arrange ophthalmologic evaluation before and during intensification, given the risk of transient retinopathy worsening with rapid correction
ANSWER: E
Rationale:
Rapid HbA1c reduction can transiently worsen pre-existing diabetic retinopathy, the phenomenon observed in SUSTAIN-6 and previously with intensive insulin therapy in the DCCT. With moderate retinopathy and a high baseline HbA1c, the appropriate approach is to pace the correction and arrange ophthalmologic evaluation before and during intensification.
Option A: Option A is incorrect because lowering HbA1c as quickly as possible is exactly what risks transient retinopathy worsening in this setting.
Option B: Option B is incorrect because indefinitely withholding treatment is not appropriate; therapy should proceed, but paced with eye surveillance.
Option C: Option C is incorrect because the rate of glycemic change is precisely the relevant factor for retinopathy worsening.
Option D: Option D is incorrect because DPP-4 inhibitors do not uniquely prevent retinopathy progression, and the issue is the pace of correction rather than the specific class.
6. A 70-year-old man with type 2 diabetes has been taking twice-daily exenatide for several years. His renal function has declined, and his estimated glomerular filtration rate (eGFR) is now 25 mL/min/1.73m2. He has tolerated the drug well and asks whether to continue. What is the most appropriate action?
A) Discontinue exenatide and, if a GLP-1 receptor agonist is still desired, switch to a human GLP-1-based agent that does not require renal dose adjustment, because exenatide is cleared renally to a greater degree and is generally avoided below an eGFR of 30
B) Continue exenatide unchanged, because GLP-1 receptor agonist clearance is independent of renal function for all agents
C) Continue exenatide but add a loop diuretic to improve its renal clearance
D) Double the exenatide dose to compensate for reduced renal elimination
E) Switch to metformin, which is preferred at this eGFR
ANSWER: A
Rationale:
Exenatide is cleared renally to a greater degree than other agents in the class and is generally avoided when the eGFR falls below 30 mL/min/1.73m2. At an eGFR of 25, the appropriate action is to discontinue exenatide and, if continued GLP-1 receptor agonist therapy is desired, switch to a human GLP-1-based agent that does not require renal dose adjustment.
Option B: Option B is incorrect because exenatide specifically is the renal-clearance exception, so the premise that all agents are independent of renal function is wrong.
Option C: Option C is incorrect because adding a loop diuretic does not safely correct the issue and is not a strategy to improve exenatide handling.
Option D: Option D is incorrect because increasing the dose with declining renal elimination would raise exposure and risk, the opposite of appropriate management.
Option E: Option E is incorrect because metformin is contraindicated below an eGFR of 30 and is not preferred at an eGFR of 25.
7. A 44-year-old woman started a once-weekly GLP-1 receptor agonist 10 weeks ago. She completed the labeled titration to the maintenance dose, but persistent nausea and intermittent vomiting continue and are interfering with her daily function despite eating small low-fat meals. She wants to keep the cardiovascular and weight benefits if possible. What is the most appropriate next step?
A) Abruptly escalate to the highest available dose to push past the nausea more quickly
B) Continue the current dose unchanged and tell her the nausea will resolve on its own no matter how long it lasts
C) Consider switching to a different agent within the class, since tolerability varies among agents, or slow the titration, and discontinue only if intolerable nausea persists after these adjustments
D) Add a long-term proton pump inhibitor as the definitive solution and make no change to the GLP-1 receptor agonist
E) Switch her to insulin immediately, since GLP-1 receptor agonist intolerance precludes any further use of the class
ANSWER: C
Rationale:
When intolerable nausea persists after adequate titration, tolerability varies among agents, so switching to a different agent within the class is a legitimate option, as is slowing the titration; discontinuation is reserved for when intolerable symptoms persist despite these adjustments. This preserves the option of retaining class benefits.
Option A: Option A is incorrect because abruptly escalating to the highest dose worsens the mechanism-based nausea rather than relieving it.
Option B: Option B is incorrect because nausea that persists and impairs function after full titration should be addressed, not simply waited out indefinitely.
Option D: Option D is incorrect because a long-term proton pump inhibitor is not the defined solution for GLP-1 receptor agonist nausea, and making no change ignores the patient's distress.
Option E: Option E is incorrect because intolerance to one agent does not preclude the entire class; a within-class switch or slower titration should be tried first.
8. A 63-year-old woman with type 2 diabetes and chronic kidney disease (eGFR 34 mL/min/1.73m2 with albuminuria) needs additional glucose lowering, and her clinician wants an agent that also offers renal protection. Which GLP-1 receptor agonist choice is best supported by dedicated renal-outcome evidence?
A) Twice-daily exenatide, because exendin-4-based agents provide the strongest renal protection
B) No GLP-1 receptor agonist, because the class is contraindicated at this eGFR
C) Any agent will do equally, since renal-outcome evidence does not differ within the class
D) Semaglutide, which is supported by the dedicated FLOW renal-outcome trial in type 2 diabetes with chronic kidney disease and requires no renal dose adjustment at this eGFR, while exenatide should be avoided as the renally cleared exception
E) A DPP-4 inhibitor instead, because it has superior dedicated renal-outcome evidence to any GLP-1 receptor agonist
ANSWER: D
Rationale:
Semaglutide is supported by the dedicated FLOW renal-outcome trial in patients with type 2 diabetes and chronic kidney disease and requires no renal dose adjustment at this eGFR, making it the best-supported choice when renal protection is a goal. Exenatide is the renally cleared exception that should be avoided below an eGFR of 30.
Option A: Option A is incorrect because exenatide is the agent to avoid here, not the most renally protective choice.
Option B: Option B is incorrect because the class is not contraindicated at an eGFR of 34; most agents are used across these stages.
Option C: Option C is incorrect because the dedicated renal-outcome evidence is agent-specific (FLOW with semaglutide), so agents are not interchangeable for this purpose.
Option E: Option E is incorrect because DPP-4 inhibitors do not have superior dedicated renal-outcome evidence to GLP-1 receptor agonists; the dedicated renal trial evidence favors semaglutide.
9. A 39-year-old woman on a high-dose GLP-1 receptor agonist has lost 14 kg over 5 months. She now reports episodic right upper quadrant pain that is worse after fatty meals, with occasional nausea. She is afebrile. Which complication should be suspected, and what is the appropriate initial step?
A) Acute pancreatitis; obtain a chest radiograph
B) Cholelithiasis or cholecystitis; obtain a right upper quadrant biliary ultrasound, recognizing that GLP-1 receptor agonists reduce gallbladder motility and that risk rises with higher doses and greater weight loss
C) Medullary thyroid carcinoma; obtain a serum calcitonin
D) Diabetic retinopathy; obtain an urgent dilated eye exam
E) Lactic acidosis; obtain a serum lactate
ANSWER: B
Rationale:
GLP-1 receptor agonists reduce gallbladder motility and increase biliary lithogenicity, and the risk of cholelithiasis and cholecystitis rises with higher doses and greater weight loss. Episodic right upper quadrant pain worse after fatty meals in a patient with substantial rapid weight loss points to gallbladder disease, and the appropriate initial step is a right upper quadrant biliary ultrasound.
Option A: Option A is incorrect because the fatty-meal-related right upper quadrant pain pattern points to biliary disease, and a chest radiograph is not the relevant initial study.
Option C: Option C is incorrect because the presentation is biliary colic, not a thyroid C-cell process, so calcitonin is not the appropriate initial step.
Option D: Option D is incorrect because the symptoms are abdominal and biliary, not visual, so an eye exam does not address this presentation.
Option E: Option E is incorrect because lactic acidosis is associated with metformin rather than GLP-1 receptor agonists and does not explain fatty-meal-related right upper quadrant pain.
10. A 58-year-old man with type 2 diabetes on basal insulin glargine has a GLP-1 receptor agonist added for weight and cardiovascular benefit. Over the next week his appetite falls noticeably and he records several fasting glucose values in the 60s mg/dL with mild morning shakiness. What is the most appropriate adjustment?
A) Discontinue the GLP-1 receptor agonist, as it directly causes fasting hypoglycemia on its own
B) Increase the glargine dose to stabilize the fasting glucose
C) Add a sulfonylurea to smooth out the glucose pattern
D) Make no change, since fasting values in the 60s are the intended target on this combination
E) Reduce the basal insulin dose by approximately 10 to 20 percent and titrate based on fasting glucose monitoring
ANSWER: E
Rationale:
When a GLP-1 receptor agonist is combined with insulin, the amplified glucose-dependent insulin effect plus reduced food intake from appetite suppression can produce hypoglycemia. With fasting values in the 60s and symptoms, the appropriate step is to reduce the basal insulin dose by roughly 10 to 20 percent and titrate based on fasting glucose monitoring.
Option A: Option A is incorrect because the GLP-1 receptor agonist does not cause fasting hypoglycemia on its own; the basal insulin is the modifiable contributor.
Option B: Option B is incorrect because increasing glargine would worsen the hypoglycemia.
Option C: Option C is incorrect because adding a sulfonylurea would further increase hypoglycemia risk.
Option D: Option D is incorrect because symptomatic fasting values in the 60s represent hypoglycemia, not an intended target.
11. A 60-year-old man on a GLP-1 receptor agonist presents with severe persistent epigastric pain radiating to the back, vomiting, and a lipase more than three times the upper limit of normal, and imaging confirms acute pancreatitis. What is the most appropriate action regarding the GLP-1 receptor agonist?
A) Discontinue the GLP-1 receptor agonist, because confirmed acute pancreatitis is an indication to stop the drug
B) Continue the GLP-1 receptor agonist at the same dose, since pancreatitis is unrelated to the class
C) Increase the GLP-1 receptor agonist dose to suppress the inflammation
D) Continue the GLP-1 receptor agonist but add a second incretin-based agent
E) Make no medication change and simply repeat the lipase in one month
ANSWER: A
Rationale:
Pancreatitis is a class precaution for incretin-based therapies, and GLP-1 receptor agonists should be discontinued when acute pancreatitis is confirmed. With a confirmed diagnosis here, stopping the drug is the appropriate action.
Option B: Option B is incorrect because confirmed acute pancreatitis is precisely the situation in which the drug should be stopped, not continued unchanged.
Option C: Option C is incorrect because increasing the dose does not treat pancreatitis and is contrary to discontinuation guidance.
Option D: Option D is incorrect because adding another incretin-based agent during confirmed acute pancreatitis is inappropriate.
Option E: Option E is incorrect because a confirmed acute pancreatitis diagnosis requires discontinuation rather than deferring any change and rechecking the lipase later.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.